Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...

Hydroxychloroquine is tied to reduced preeclampsia risk but not preterm birth risk in pregnant patients with lupus in a ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved label updates for ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...